Metformin hydrochloride

SKU: orb1310334

Description

Metformin hydrochloride (1,1-Dimethylbiguanide hydrochloride) is a blood-brain barrier permeable AMPK activator widely used in type 2 diabetes research. It improves glycemic control by enhancing insulin sensitivity and reducing intestinal glucose absorption, and is also investigated in metabolic, aging, and oncology studies using in vitro and in vivo models.

Research Area

Cell Biology, Epigenetics & Chromatin, Pharmacology & Drug Discovery, Signal Transduction

Images & Validation

−

Key Properties

−

CAS Number	1115-70-4
MW	165.63
Purity	97.53% (May vary between batches)
Formula	C₄H₁₂ClN₅
SMILES	Cl.CN(C)C(=N)NC(N)=N
Target	Autophagy,AMPK,mTOR,Mitophagy,Apoptosis
Solubility	H2O:193.21 mM;DMSO:50 mg/mL (301.88 mM)

Customer Validated Data

−

The data below is submitted by researchers worldwide. We provide this transparency to help you decide if this product works for your specific application or species, even if we haven't tested it ourselves.

Success by Application

Reactivity Distribution

Latest Experiments

5 Results

Dilution

Sample

Summary

In vitro

Human

20 µM

Primary cancer cells

Metformin was used to study chemosensitization...

In vitro

Human

5 mM

HT29, HCT116, and HCT116 p53−/− cell lines

Metformin was used to study anti-cancer...

In vivo

Mouse

250–1000 mg/kg/day

Oral administration

Metformin (Combi-Blocks) was used to induce...

In vitro

Human

30 μM & 100 μM

Primary alveolar BMSCs

Metformin was used to improve the...

In vivo

Mouse

100 mg/kg/day

Oral administration

Metformin was used to investigate its...

Bioactivity

−

Target IC50	MDA-MB-231 cells:149 mM\|HepG2 cells:98 mM\|MYCN-2 cells:> 100 mM\|SK-N-Be2c cells:> 100 mM
In Vivo	METHODS: To model Metformin-induced diarrhea, Metformin hydrochloride (125-500 mg/kg) was administered orally to healthy and diabetic obese db/db C57BL/6J mice twice daily for thirteen days. RESULTS: Metformin at 1000 mg/kg/day significantly increased fecal water content. Although no diarrhea symptoms were observed in healthy C57BL/6J mice, the same dose of Metformin induced severe diarrhea in diabetic obese db/db mice. METHODS: To investigate the protective effect of Metformin in radiation injury, Metformin hydrochloride (200 mg/kg once daily for three days) was administered orally to BALB/c mice, which were then exposed to 6-8 Gy of gamma radiation. RESULTS: When administered prior to exposure to radiation, Metformin prolonged the survival of mice exposed to 8 Gy-TBI and increased the survival of mice exposed to 6 Gy-TBI. Pretreatment with Metformin attenuated radiation damage. Read more...
In Vitro	METHODS: Ovarian cancer cells A2780 and SKOV3 were treated with Metformin hydrochloride (0.001-50 mM) for 24-48 h. Cell viability was assayed using the MTS RESULTS: Micromolar concentrations of Metformin did not statistically reduce the viability of the A2780 or SKOV3 cell lines. At 48 h, millimolar concentrations resulted in cell death. METHODS: Human colorectal cancer cells HCT29 were treated with Metformin hydrochloride (0.6 mM) for 90 h. Cell motility was detected using the wound healing assay and chamber invasion assay. RESULTS: Metformin inhibited the migration and invasion of HCT29 cells, and Metformin decreased the motility of tumor cells. Read more...
Cell Research	Hepatocytes were isolated from male Sprague Dawley (SD) rats by collagenase digestion. For the AMPK assay, cells were seeded in six-well plates at 1.5 × 10^6 cells/well in DMEM containing 100 U/ml penicillin, 100 μg/ml streptomycin, 10% FBS, 100 nM insulin, 100 nM dexamethasone, and 5 μg/ml transferrin for 4 hours. Cells were then cultured in serum-free DMEM for 16 hours followed by treatment for 1 hour or 7 hours with control medium, 5-aminoimidazole carboxamide riboside (AICAR), or metformin at concentrations indicated. For a 39-hour treatment, cells for both control and metformin (10 or 20 μM) groups were cultured in DMEM plus 5% FBS and 100 nM insulin, and the fresh control and metformin-containing medium were replaced every 12 hours (last medium change was 3 hours before harvest). After treatment, the cells were directly lysed in digitonin-containing and phosphatase inhibitor–containing buffer A, followed by precipitation with ammonium sulfate at 35% saturation. AMPK activity was determined by measurement of phosphorylation of a synthetic peptide substrate, SAMS (HMRSAMSGLHLVKRR). For ACC assay, the 35% ammonium sulfate precipitate from digitonin-lysed hepatocytes (4 μg each) was used for determination of ACC activity via 14CO2 fixation in the presence of 20 mM citrate as done previously. For fatty acid oxidation, the oxidation of 14C-oleate to acid-soluble products was performed as done previously, but in medium M199 in the absence of albumin . Read more...
Animal Research	Oral gavage was used to administer 1 ml of metformin (100 mg/ml) or water alone to male SD rats (300–350 g, n = 7–8). Rats were treated once or twice a day for 5 days. Rats were starved for 20 hours and then re-fed for 2 hours before the final dose; 4 hours after the final dose, the animals were anesthetized and livers rapidly removed by freeze clamping followed by blood withdrawal. RNA was prepared from the freeze-clamped liver by RNA isolation reagent. Nuclear extracts were prepared from a pool of seven rat livers. Glucose levels were determined using the standard glucose oxidase assay kit; β-hydroxybutyrate concentrations were assayed by measuring the reduction of NAD to NADH with a standard assay kit. FFA levels were measured with the assay kit . MCF10A-ER-Src cells (5 × 10^6) were injected into the right flank of 18 female nu/nu mice, all of which developed tumors in 10 d with a size of ～100 mm^3. The mice were randomly distributed into six groups (three mice/group) that were untreated or treated by intratumoral injections every 5 d (four cycles) with 1 mg/kg or 4 mg/kg doxorubicin, 200 μg/mL metformin (diluted in the drinking water), or the combination. In another experiment, LNCaP and DU145 prostate cancer cells (5 × 10^6) were injected into the right flank of 12 female nu/nu mice, all of which developed tumors in 10 d with a size of ～75 mm^3. The mice were randomly distributed into four groups that were untreated or treated by intratumoral injections every 5 d (four cycles) with 4 mg/kg doxorubicin and/or 200 μg/mL metformin. In another experiment, A375 and MDA-MB-435 melanoma cells (7 × 10^6) were injected into the right flank of 12 female nu/nu mice, all of which developed tumors in 10 d with a size of ～50 mm3. The mice were randomly distributed into four groups that were untreated or treated by intratumoral injections every 5 d (four cycles) with 10 mg/kg cisplatin and/or 200 μg/mL metformin.Finally, SNU-449 liver cancer cells (10^7) were injected into the right flank of 12 female nu/nu mice, all of which developed tumors in 10 d with a size of ～50 mm^3. The mice were randomly distributed into four groups that were untreated or treated by intratumoral injections every 5 d (four cycles) with 10 mg/kg cisplatin and/or 200 μg/mL metformin. Tumor volume (mean ± SD) was measured at various times after the initial injection . Read more...

Storage & Handling

−

Storage	-20°C
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

diabetes, chain, 1,1-Dimethylbiguanide Hydrochloride, 1,1-Dimethylbiguanide hydrochloride, 1,1-Dimethylbiguanide, 1, 1-Dimethylbiguanide Hydrochloride, 1, 1-Dimethylbiguanide hydrochloride, AMPK, AMP-activated protein kinase, Autophagy, barrier, blood-brain, insulin, Metformin, Metformin HCl, Metformin hydrochloride, Metformin Hydrochloride, Mitophagy, Mitochondrial Autophagy, mitochondrial, Inhibitor, inhibit, liver, type, respiratory, sensitivity

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Compound Identifiers

PubChem CID

137704554 ↗

Key Properties

−

No computed properties available.

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols